We confirmed that nifurtimox is converted to a more potent drug by a parasite enzyme and, as also reported independently by other groups, found that eflornithine is taken up by a parasite amino acid transporter.
A much older drug, suramin, was found to hitch-a-ride into the cell on a parasite surface protein. This was a particularly satisfying discovery because Paul Ehrlich, "the father of chemotherapy," who developed both the "magic bullet" hypothesis and the precursors to suramin over 100 years ago, stated, "When once we are acquainted with the majority of the chemioreceptors of a particular kind of parasite. . .we shall have far-reaching possibilities of simultaneous attack by various agencies" (Ehrlich, 1913) . So, we found one of Ehrlich's "chemioreceptors," and this does indeed present new opportunities for therapeutic development.
Another finding related to two more old drugs for which cross-resistance had been reported over 60 years ago. This melarsoprol and pentamidine cross-resistance was linked to a defect in an aquaglyceroporin, another parasite membrane transporter. Resistance to melarsoprol, a rather toxic but otherwise effective arsenic-containing drug, had been observed in up to 50% of patients in some areas. Teams that collected and stored resistant parasites from across Africa were able to rapidly identify defects in this transporter and to trace them back to the mid-1970s. Thus, the genetic changes that allowed trypanosomes to resist this particular therapy are now known, the impact of these changes can be investigated in detail, and the spread and distribution of resistant parasites can be effectively monitored.
It's quite remarkable how biological processes frequently become experimentally accessible in unanticipated ways, probably because we still have so much to learn about many of them. This has also been my personal experience. In the case of our own findings, it was our work on DNA repair that allowed us to develop the genetic screening approach described above. In addition, our initial motivation for developing this approach was a desire to tackle a completely different gene expression question; fortunately, we were able to initiate collaborations with colleagues who were already established experts in drug resistance.
What is clear is that knowing how drugs work and how they stop working helps improve the prospects of devising more effective and durable therapies and also improves prospects for monitoring and tackling resistance when it arises. As primarily "basic researchers," working with partners in the Dundee Drug Discovery Unit, we will continue our efforts to discover and dissect druggable biology in the trypanosomatids. Indeed, tools and technologies are now in place to probe these chemical-biology interactions at higher throughput than ever before.
Since our work continuously relies upon the work and discoveries of many colleagues-too many to mention, I'm afraid-I end by reiterating what's probably rather obvious: impact against these and other human and animal pathogens requires a community of researchers, critical mass, open interaction, collaboration, and access to powerful technology, at both basic and translational levels. What is also clear is that experiments with pathogens will continue to yield insights of far broader relevance to the life sciences and beyond.
